Identification and molecular characterization of two novel mutations in COL1A2 in two Chinese families with osteogenesis imperfecta

Zhenping Xu; Yulei Li; Xiangyang Zhang; Fanming Zeng; Mingxiong Yuan; Mugen Liu; Qing Kenneth Wang; Jing Yu Liu

doi:10.1016/j.jgg.2011.03.002

Volume 38 Issue 4

Apr. 2011

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2011 > 38(4): 149-156

PDF( 880 KB)

Identification and molecular characterization of two novel mutations in COL1A2 in two Chinese families with osteogenesis imperfecta

doi: 10.1016/j.jgg.2011.03.002

a
Key Laboratory of Molecular Biophysics of the Ministry of Education, Center for Human Genome Research, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
b
Key Open Laboratory for Tissue Regeneration of Henan Universities, Department of Life Science and Technique, Xinxiang Medical University, Xinxiang 453003, China
c
Department of Molecular Cardiology, Cleveland Clinic, Cleveland, OH 44195, USA

More Information

Corresponding author: E-mail address: qkwang@mail.hust.edu.cn (Qing Kenneth Wang); E-mail address: liujy@mail.hust.edu.cn (Jing Yu Liu)
Received Date: 2010-08-10
Accepted Date: 2011-03-06
Rev Recd Date: 2011-01-21

Available Online: 2011-03-24

Publish Date: 2011-04-20

Abstract

Abstract

Osteogenesis imperfecta (OI, also known as brittle bone disease) is caused mostly by mutations in two type I collagen genes, COL1A1 and COL1A2 encoding the pro-α1 (I) and pro-α2 (I) chains of type I collagen, respectively. Two Chinese families with autosomal dominant OI were identified and characterized. Linkage analysis revealed linkage of both families to COL1A2 on chromosome 7q21.3-q22.1. Mutational analysis was carried out using direct DNA sequence analysis. Two novel missense mutations, c.3350A>G and c.3305G>C, were identified in exon 49 ofCOL1A2 in the two families, respectively. The c.3305G>C mutation resulted in substitution of a glycine residue (G) by an alanine residue (A) at codon 1102 (p.G1102A), which was found to be mutated into serine (S), argine (R), aspartic acid (D), or valine (V) in other families. The c.3350A>G variant may be ade novo mutation resulting in p.Y1117C. Both mutations co-segregated with OI in respective families, and were not found in 100 normal controls. The G1102 and Y1117 residues were evolutionarily highly conserved from zebrafish to humans. Mutational analysis did not identify any mutation in theCOX-2 gene (a modifier gene of OI). This study identifies two novel mutations p.G1102A and p.Y1117C that cause OI, significantly expands the spectrum of COL1A2 mutations causing OI, and has a significant implication in prenatal diagnosis of OI.
- Osteogenesis imperfecta,
- Mutation

These authors contributed equally to this study.

FullText(HTML)

References(37)

References

[1]	Alanay, Y., Avaygan, H., Camacho, N. et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta Am. J. Hum. Genet., 86 (2010),pp. 551-559
[2]	Baldridge, D., Schwarze, U., Morello, R. et al. Hum. Mutat., 29 (2008),pp. 1435-1442
[3]	Basel, D., Steiner, R.D. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition Genet. Med., 11 (2009),pp. 375-385
[4]	Bodian, D.L., Madhan, B., Brodsky, B. et al. Predicting the clinical lethality of osteogenesis imperfecta from collagen glycine mutations Biochemistry, 47 (2008),pp. 5424-5432
[5]	Bodian, D.L., Chan, T.F., Poon, A. et al. Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships Hum. Mol. Genet., 18 (2009),pp. 463-471
[6]	Bossolasco, P., Montemurro, T., Cova, L. et al. Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential Cell Res., 16 (2006),pp. 329-336
[7]	Brooks, P., Marcaillou, C., Vanpeene, M. et al. Robust physical methods that enrich genomic regions identical by descent for linkage studies: confirmation of a locus for osteogenesis imperfecta BMC Genet., 10 (2009),p. 16
[8]	Cabral, W.A., Chang, W., Barnes, A.M. et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta Nat. Genet., 39 (2007),pp. 359-365
[9]	Christiansen, H.E., Schwarze, U., Pyott, S.M. et al. Am. J. Hum. Genet., 86 (2010),pp. 389-398
[10]	Dai, X., Gao, Y., Xu, Z. et al. Identification of a novel genetic locus on chromosome 8p21.1-q11.23 for idiopathic basal ganglia calcification Am. J. Med. Genet. B. Neuropsychiatr. Genet., 153B (2010),pp. 1305-1310
[11]	Dimasi, D.P., Chen, J.Y., Hewitt, A.W. et al. Novel quantitative trait loci for central corneal thickness identified by candidate gene analysis of osteogenesis imperfecta genes Hum. Genet., 127 (2010),pp. 33-44
[12]	Faqeih, E., Roughley, P., Glorieux, F.H. et al. Am. J. Med. Genet. A, 149A (2009),pp. 461-465
[13]	Hall, C.M. International nosology and classification of constitutional disorders of bone (2001) Am. J. Med. Genet., 113 (2002),pp. 65-77
[14]	Hartikka, H., Kuurila, K., Körkkö, J. et al. Hum. Mutat., 24 (2004),pp. 147-154
[15]	Hsieh, C.T., Yeh, G.P., Wu, H.H. et al. Fetus with osteogenesis imperfecta presenting as increased nuchal translucency thickness in the first trimester J. Clin. Ultrasound, 36 (2008),pp. 119-122
[16]	Lee, K.S., Song, H.R., Cho, T.J. et al. Mutational spectrum of type I collagen genes in Korean patients with osteogenesis imperfecta Hum. Mutat., 27 (2006),p. 599
[17]	Li, C., 2009. Increased Bone Mineral Density and Body Mass Index in Families of Osteogenesis Imperfecta. ASHG Meeting 2009 Program Number: 2630 (https://oi.gene.le.ac.uk).
[18]	Lu, J., Costa, T., Cole, W.G. A novel G1006A substitution in the alpha 2(I) chain of type I collagen produces osteogenesis imperfecta type III Hum. Mutat., 5 (1995),pp. 175-178
[19]	Lund, A.M., Skovby, F., Schwartz, M. Deletion of a Gly-Pro-Pro repeat in the pro alpha2(I) chain of procollagen I in a family with dominant osteogenesis imperfecta type IV Hum. Genet., 97 (1996),pp. 287-290
[20]	Marini, J.C., Forlino, A., Cabral, W.A. et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans Hum. Mutat., 28 (2007),pp. 209-221
[21]	Martin, E., Shapiro, J.R. Osteogenesis imperfecta: epidemiology and pathophysiology Curr. Osteoporos. Rep., 5 (2007),pp. 91-97
[22]	Monti, E., Mottes, M., Fraschini, P. et al. Current and emerging treatments for the management of osteogenesis imperfecta Ther. Clin. Risk Manag., 6 (2010),pp. 367-381
[23]	Morello, R., Bertin, T.K., Chen, Y. et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta Cell, 127 (2006),pp. 291-304
[24]	Morgan, J.A., Marcus, P.S. Prenatal diagnosis and management of intrauterine fracture Obstet. Gynecol. Surv., 65 (2010),pp. 249-259
[25]	Oliver, J.E., Thompson, E.M., Pope, F.M. et al. Mutation in the carboxy-terminal propeptide of the Pro alpha 1(I) chain of type I collagen in a child with severe osteogenesis imperfecta (OI type III): possible implications for protein folding Hum. Mutat., 7 (1996),pp. 318-326
[26]	Pace, J.M., Atkinson, M., Willing, M.C. et al. Deletions and duplications of Gly-Xaa-Yaa triplet repeats in the triple helical domains of type I collagen chains disrupt helix formation and result in several types of osteogenesis imperfecta Hum. Mutat., 18 (2001),pp. 319-326
[27]	Pace, J.M., Wiese, M., Drenguis, A.S. et al. Defective C-propeptides of the proalpha2(I) chain of type I procollagen impede molecular assembly and result in osteogenesis imperfecta J. Biol. Chem., 283 (2008),pp. 16061-16067
[28]	Phillipi, C.A., Remmington, T., Steiner, R.D. Bisphosphonate therapy for osteogenesis imperfecta Cochrane Database Syst. Rev., 4 (2008),p. CD005088
[29]	Ponnapakkam, T.P., Sledge, D., Gensure, R., 2006. A novel COL1A2 mutation leading to osteogenesis imperfecta type 1 in identical twins. Pediatrics Ochsner Clinic Foundation, New Orleans, LA. (http://www.ashg.org/genetics/ashg06s/f30600.htm).
[30]	Rauch, F., Glorieux, F.H. Osteogenesis imperfecta Lancet, 363 (2004),pp. 1377-1385
[31]	Rauch, F., Lalic, L., Roughley, P. et al. Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I Eur. J. Hum. Genet., 18 (2010),pp. 642-647
[32]	Roschger, P., Fratzl-Zelman, N., Misof, B.M. et al. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations Calcif. Tissue Int., 82 (2008),pp. 263-270
[33]	Sillence, D.O., Senn, A., Danks, D.M. Genetic heterogeneity in osteogenesis imperfecta J. Med. Genet., 16 (1979),pp. 101-116
[34]	Solopova, A., Wisser, J., Huisman, T.A. Osteogenesis imperfecta type II: fetal magnetic resonance imaging findings Fetal Diagn. Ther., 24 (2008),pp. 361-367
[35]	van Dijk, F.S., Nesbitt, I.M., Zwikstra, E.H. et al. PPIB mutations cause severe osteogenesis imperfecta Am. J. Hum. Genet., 85 (2009),pp. 521-527
[36]	Wenstrup, R.J., Cohn, D.H., Cohen, T. et al. J. Biol. Chem., 263 (1988),pp. 7734-7740
[37]	Witecka, J., Auguściak-Duma, A.M., Kruczek, A. et al. J. Appl. Genet., 49 (2008),pp. 283-295